Trials / Completed
CompletedNCT00234078
Dose-response Study of OPC-12759 Ophthalmic Suspension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 290 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension in dry eye patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 0.5% OPC-12759 | |
| DRUG | 1% OPC-12759 | |
| DRUG | 2% OPC-12759 | |
| DRUG | placebo |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2006-04-01
- Completion
- 2007-03-01
- First posted
- 2005-10-06
- Last updated
- 2014-02-28
- Results posted
- 2014-02-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00234078. Inclusion in this directory is not an endorsement.